HDAC9 and cancer: The drugs used to test the AI co‐scientist selected epigenomic targets were: a selective DNA methyl transferase 1 (DNMT1) inhibitor (GSK3685032) that is less toxic and has more durable hypomethylating effects than prior DNMT inhibitors;[23] an FDA‐approved anti‐cancer drug that is a pan‐histone deacetylase (HDAC) inhibitor (Vorinostat or SAHA);[24] and three BRD4 inhibitors: JQ1 (an early BRD4 inhibitor),[25] and two (I‐BET762 (GSK525762),[26] ZEN‐3694[27]) with improved risk‐benefit profiles.